Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
10 November 2021Website:
http://www.bluejaydx.comNext earnings report:
16 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 10 min agoDividend
Analysts recommendations
Institutional Ownership
BJDX Latest News
ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consisted of 5,368,098 Common Units or Prefunded Units, each Unit consisting of one share of the Company's common stock (“Common Stock”) or one pre-funded warrant to purchase one share of Common Stock (each, a “Prefunded Warrant”), two Class C warrants each to purchase one share of our common stock (each, a “Class C Warrant”) and one Class D Warrant to purchase such number of shares of common stock as determined in the Class D Warrant (each, a “Class D Warrant” and together with the Class C Warrants, the “Common Warrants”). The purchase price of each Common Unit is $1.63, and the purchase price of each Prefunded Unit is $1.6299 (which is equal to the public offering price per Common Unit minus $0.0001). The Prefunded Warrants will be immediately exercisable and may be exercised at any time until all the Prefunded Warrants are exercised in full.
Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU). Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU).
Bluejay Diagnostics (NASDAQ: BJDX ) stock is rising higher on Friday despite a lack of news from the medical diagnostic company. There have been no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is rallying this morning.
What type of business is Bluejay Diagnostics?
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
What sector is Bluejay Diagnostics in?
Bluejay Diagnostics is in the Healthcare sector
What industry is Bluejay Diagnostics in?
Bluejay Diagnostics is in the Medical Devices industry
What country is Bluejay Diagnostics from?
Bluejay Diagnostics is headquartered in United States
When did Bluejay Diagnostics go public?
Bluejay Diagnostics initial public offering (IPO) was on 10 November 2021
What is Bluejay Diagnostics website?
https://www.bluejaydx.com
Is Bluejay Diagnostics in the S&P 500?
No, Bluejay Diagnostics is not included in the S&P 500 index
Is Bluejay Diagnostics in the NASDAQ 100?
No, Bluejay Diagnostics is not included in the NASDAQ 100 index
Is Bluejay Diagnostics in the Dow Jones?
No, Bluejay Diagnostics is not included in the Dow Jones index
When does Bluejay Diagnostics report earnings?
The next expected earnings date for Bluejay Diagnostics is 16 August 2024